Alpha-1 Foundation Ireland was founded in 2001 and is based in the RCSI Education and Research Centre at Beaumont Hospital.
Vision
That every Alpha-1 individual in Ireland is diagnosed and receives specialist care and treatment in a timely fashion.
Mission Statement
Alpha-1 Foundation Ireland is dedicated to raising awareness, increasing diagnosis, promoting research, and improving the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Background
Alpha-1 Foundation Ireland was founded to raise awareness, increase diagnosis, promote research, and improve the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Alpha-1 is a genetic condition that can cause severe lung and liver problems. It is one of the most common inherited conditions in Ireland but unfortunately Alpha-1 is hugely under-diagnosed. For example, the typical person with Alpha-1 sees up to 5 doctors for a period of 7 years before a correct diagnosis is reached. Alpha-1 affects approximately 250,000 people on the island of Ireland, with 3,000 of these affected by severe deficiency (The Prevalence of Alpha-1 Antitrypsin Deficiency in Ireland, Respiratory Research, 2011 July 13;12:91). People with Alpha-1 sometimes present in their 40s and 50s with early-onset emphysema or chronic obstructive pulmonary disease (COPD) but lung disease can also occur later in life. A sub-group of people with severe Alpha-1 (usually ZZ) present with liver disease in the first year of life and in rare cases may require liver transplantation. Early diagnosis is vital to the health and welfare of people with Alpha-1, and this is our main objective.
Alpha-1 Foundation Ireland works closely with Health Research Charities Ireland (HRCI), the Irish Platform for Patient Organisations, Science, and Industry (IPPOSI), the Irish Donor Network, the Asthma Society, COPD Support Ireland and several other organisations dedicated to improving lung and liver health. We support our active Alpha-1 patient support group which promotes understanding and awareness of the condition among patients and their families, as well as providing much needed peer-to-peer support for newly-diagnosed Alphas.
Our main aims include:
Increasing awareness of Alpha-1 Antitrypsin Deficiency (Alpha-1), amongst both the medical profession and the general public.
Promoting early diagnosis of Alpha-1 individuals.
Providing comprehensive patient support.
Access to clinical trials for emerging therapies.
National Alpha-1 Screening Programme:
In 2004 we began a national screening programme funded by the Department of Health and Children to reduce the under diagnosis and misdiagnosis of Alpha-1. This targeted detection programme is the only national screening programme for Alpha-1 in the world. We follow World Health Organisation (WHO), American Thoracic Society (ATS), and European Respiratory Society (ERS) guidelines which together recommend testing of:
All chronic obstructive pulmonary disease (COPD) patients
All non-responsive asthmatics
All cryptogenic liver disease patients
All first-degree relatives of known Alphas
Individuals with reduced serum levels of AAT
Panniculitis patients
There is a dedicated Alpha-1 clinic under the care of Professor McElvaney in Beaumont Hospital every Wednesday afternoon. The staff of the Alpha-1 Foundation use the latest diagnostic methods in our screening programme, perform research in the area of Alpha-1, coordinate clinical trials testing new therapies, and strive to increase awareness of the condition throughout Ireland. Staff members liaise with the Alpha-1 clinic team, as well as patients, GPs, hospital laboratory staff, and respiratory and liver specialists throughout Ireland.
As Alpha-1 is a hereditary condition we strongly recommend that first degree family members of people diagnosed with Alpha-1 should be tested as relatives may also be affected and at risk of lung or liver disease.
Staff of Alpha-1 Foundation Ireland:
Anne Marie O’Dowd, CEO
Dr. Tomás Carroll, chief scientist (Senior Lecturer, RCSI)
Ronan Heeney, medical scientist
Rosaleen Carroll, Alpha-1 nurse specialist
Board of Alpha-1 Foundation Ireland:
Professor Shane O’Neill (Chairperson)
Michelle Hughes (person living with Alpha-1)
Kathryn Fenlon (Secretary)
Professor Gerry McElvaney
Patron of Alpha-1 Foundation Ireland:
President of Ireland Michael D. Higgins.
Contact Us:
Please contact us with any queries on 01-8093871 or email alpha1@rcsi.ie.
Info Centre
WhatisAlpha-1Antitrypsin?
Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.
WhatisAlpha-1AntitrypsinDeficiency?
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).
HowDoIGetTested?
The Alpha-1 Foundation Ireland provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. It is a simple blood test. For more details ring 01-8093871 or email alpha1@rcsi.ie
About us
Organisation
Alpha-1 Foundation Ireland was founded in 2001 and is based in the RCSI Education and Research Centre at Beaumont Hospital.
Vision
That every Alpha-1 individual in Ireland is diagnosed and receives specialist care and treatment in a timely fashion.
Mission Statement
Alpha-1 Foundation Ireland is dedicated to raising awareness, increasing diagnosis, promoting research, and improving the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Background
Alpha-1 Foundation Ireland was founded to raise awareness, increase diagnosis, promote research, and improve the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Alpha-1 is a genetic condition that can cause severe lung and liver problems. It is one of the most common inherited conditions in Ireland but unfortunately Alpha-1 is hugely under-diagnosed. For example, the typical person with Alpha-1 sees up to 5 doctors for a period of 7 years before a correct diagnosis is reached. Alpha-1 affects approximately 250,000 people on the island of Ireland, with 3,000 of these affected by severe deficiency (The Prevalence of Alpha-1 Antitrypsin Deficiency in Ireland, Respiratory Research, 2011 July 13;12:91). People with Alpha-1 sometimes present in their 40s and 50s with early-onset emphysema or chronic obstructive pulmonary disease (COPD) but lung disease can also occur later in life. A sub-group of people with severe Alpha-1 (usually ZZ) present with liver disease in the first year of life and in rare cases may require liver transplantation. Early diagnosis is vital to the health and welfare of people with Alpha-1, and this is our main objective.
Alpha-1 Foundation Ireland works closely with Health Research Charities Ireland (HRCI), the Irish Platform for Patient Organisations, Science, and Industry (IPPOSI), the Irish Donor Network, the Asthma Society, COPD Support Ireland and several other organisations dedicated to improving lung and liver health. We support our active Alpha-1 patient support group which promotes understanding and awareness of the condition among patients and their families, as well as providing much needed peer-to-peer support for newly-diagnosed Alphas.
Our main aims include:
National Alpha-1 Screening Programme:
In 2004 we began a national screening programme funded by the Department of Health and Children to reduce the under diagnosis and misdiagnosis of Alpha-1. This targeted detection programme is the only national screening programme for Alpha-1 in the world. We follow World Health Organisation (WHO), American Thoracic Society (ATS), and European Respiratory Society (ERS) guidelines which together recommend testing of:
There is a dedicated Alpha-1 clinic under the care of Professor McElvaney in Beaumont Hospital every Wednesday afternoon. The staff of the Alpha-1 Foundation use the latest diagnostic methods in our screening programme, perform research in the area of Alpha-1, coordinate clinical trials testing new therapies, and strive to increase awareness of the condition throughout Ireland. Staff members liaise with the Alpha-1 clinic team, as well as patients, GPs, hospital laboratory staff, and respiratory and liver specialists throughout Ireland.
As Alpha-1 is a hereditary condition we strongly recommend that first degree family members of people diagnosed with Alpha-1 should be tested as relatives may also be affected and at risk of lung or liver disease.
Staff of Alpha-1 Foundation Ireland:
Board of Alpha-1 Foundation Ireland:
Patron of Alpha-1 Foundation Ireland:
President of Ireland Michael D. Higgins.
Contact Us:
Please contact us with any queries on 01-8093871 or email alpha1@rcsi.ie.
Info Centre
What is Alpha-1 Antitrypsin?
Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.
What is Alpha-1 Antitrypsin Deficiency?
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).
How Do I Get Tested?
The Alpha-1 Foundation Ireland provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. It is a simple blood test. For more details ring 01-8093871 or email alpha1@rcsi.ie